Safety and efficacy extension study of daclizumab high yield process (DAC HYP) to treat relapsing remitting multiple sclerosis ClinicalTrials.gov, 9 Aug 2012 Accessed on 26 Apr 2013 from http://clinicaltrials.gov/ct2/show/record/NCT01051349. CommentRecommendBookmarkWatch